Feroze Ujjainwalla
Overview
Explore the profile of Feroze Ujjainwalla including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
464
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moningka R, Romero F, Hastings N, Guo Z, Wang M, Di Salvo J, et al.
Bioorg Med Chem Lett
. 2020 Sep;
30(23):127510.
PMID: 32898693
Here, we report the discovery of a new class of NPBWR1 antagonists identified from a fragment-based screen. Compound 1 (cAMP IC = 250 µM; LE = 0.29) emerged as an...
2.
Liu P, Wang L, DuBois B, Colandrea V, Liu R, Cai J, et al.
ACS Med Chem Lett
. 2019 Jan;
9(12):1193-1198.
PMID: 30613325
We report herein the design and synthesis of a series of orally active, liver-targeted hypoxia-inducible factor prolyl hydroxylase (HIF-PHD) inhibitors for the treatment of anemia. In order to mitigate the...
3.
Liu W, Hussain Z, Zang Y, Sweis R, Romero F, Finke P, et al.
ACS Med Chem Lett
. 2018 Nov;
9(11):1088-1093.
PMID: 30429950
A series of structurally diverse azaspirodecanone and spirooxazolidinone analogues were designed and synthesized as potent and selective somatostatin receptor subtype 5 (SSTR5) antagonists. Four optimized compounds each representing a subseries...
4.
Hoyt S, Taylor J, London C, Ali A, Ujjainwalla F, Tata J, et al.
Bioorg Med Chem Lett
. 2017 Apr;
27(11):2384-2388.
PMID: 28416132
We report the discovery and hit-to-lead optimization of a structurally novel indazole series of CYP11B2 inhibitors. Benchmark compound 34 from this series displays potent inhibition of CYP11B2, high selectivity versus...
5.
Zhu C, Wang L, Zhu Y, Guo Z, Liu P, Hu Z, et al.
Bioorg Med Chem Lett
. 2017 Feb;
27(5):1124-1128.
PMID: 28185720
The paper describes the SAR/SPR studies that led to the discovery of phenoxy cyclopropyl phenyl acetamide derivatives as potent and selective GPR119 agonists. Based on a cis cyclopropane scaffold discovered...
6.
Lombardo M, Bender K, London C, Plotkin M, Kirkland M, Mane J, et al.
Bioorg Med Chem Lett
. 2017 Feb;
27(5):1333.
PMID: 28169160
No abstract available.
7.
Petrilli W, Hoyt S, London C, McMasters D, Verras A, Struthers M, et al.
ACS Med Chem Lett
. 2017 Jan;
8(1):128-132.
PMID: 28105288
Herein we report the discovery and hit-to-lead optimization of a series of spirocyclic piperidine aldosterone synthase (CYP11B2) inhibitors. Compounds from this series display potent CYP11B2 inhibition, good selectivity versus related...
8.
Adams G, Velazquez F, Jayne C, Shah U, Miao S, Ashley E, et al.
ACS Med Chem Lett
. 2017 Jan;
8(1):96-101.
PMID: 28105282
GPR120 (FFAR4) is a fatty acid sensing G protein coupled receptor (GPCR) that has been identified as a target for possible treatment of type 2 diabetes. A selective activator of...
9.
Cox J, Chu H, Chelliah M, Debenham J, Eagen K, Lan P, et al.
ACS Med Chem Lett
. 2017 Jan;
8(1):49-54.
PMID: 28105274
Type 2 diabetes mellitus (T2DM) is an ever increasing worldwide epidemic, and the identification of safe and effective insulin sensitizers, absent of weight gain, has been a long-standing goal of...
10.
Guo L, Parker D, Zang Y, Sweis R, Liu W, Sherer E, et al.
ACS Med Chem Lett
. 2016 Dec;
7(12):1107-1111.
PMID: 27994747
GPR142 has been identified as a potential glucose-stimulated insulin secretion (GSIS) target for the treatment of type 2 diabetes mellitus (T2DM). A class of triazole GPR142 agonists was discovered through...